Initiate IND-enabling studies for two preclinical gene therapy product candidates
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Aug 2023
- Due
- 31 Dec 2023
- Checked
- 2 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company intends to initiate IND-enabling studies in the second half of 2023.”
What we found
Evidence strength A What the grades mean
The company did not initiate the IND-enabling studies in the second half of 2023; later filings indicate these studies are scheduled for completion by the end of 2025.
-
A Abeona Therapeutics Inc. 10-K filed 2025-03-20
“IND-enabling efficacy and toxicology animal studies are scheduled to be completed by the end of 2025.” ✓ confirmed on the page
Market reaction: the shares moved -3.1% against the S&P 500 over the three sessions around the disclosure (19 Mar 2025 to 24 Mar 2025). What this measures
Checked 2 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- IND-enabling studies
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Abeona Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ABEO-003395 · Corrections policy